Press Release FeedGet the RSS feed
Menu

Business Wire

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 2026

Business Wire

Clinical and preclinical presentations reflect the company's ongoing exploration of peripheral neuropathic pain

FRANKFURT, Germany, October 26, 2026--Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics' growing presence in neuropathic pain.

In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488). More weeks with ≥30% and ≥50% pain reduction were observed in the incobotulinumtoxinA group than in the placebo group. 1, However, the primary endpoint of the PaiNT trial, combining the outcome of the PHN and PS/PTNP population, did not significantly separate from placebo. In the PS/PTNP population, the heterogeneity of underlying diagnoses made the comparison with placebo inconclusive. 1,4

Most treatment-emergent adverse events were mild or moderate; treatment-related events were uncommon, and no serious treatment-related adverse events occurred. Tolerability was rated as good or very good for 72.7% of patients receiving incobotulinumtoxinA and 74.6% receiving placebo.2 In patients with PHN, incobotulinumtoxinA was also associated with stable emotional outcomes and improvements in pain-related interference with daily functioning.3

"Neuropathic pain is complex and often has a significant impact on patients' daily lives," said Stefan Albrecht, CSO, Merz Therapeutics. "The breadth of research we are presenting at IASP reflects our work to better understand both the clinical experience of patients and how incobotulinumtoxinA may act on biological pathways involved in neuropathic pain. Our broader research is helping us explore potential mechanisms and inform the next steps in our pain research program."

Beyond PaiNT, Merz Therapeutics is presenting research exploring how botulinum neurotoxin type A (BoNT/A) may influence biological pathways involved in neuropathic pain. In human sensory-neuron models, BoNT/A reduced neuronal excitability, with findings pointing towards potential effects on sodium, calcium, and TRPV1 ion-channel pathways involved in neuropathic pain signaling.5 Complementary preclinical research demonstrated incobotulinumtoxinA effects on spinal glutamate levels and molecular targets associated with inflammation and pain signaling, providing further insights into potential mechanisms for future investigation.6,7

  1. AINet Asset Value(s)Business Wire Mon, October 26, 2026 at 11:12 AM GMT+2 LONDON, October 26, 2026--Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Artificial Intelligence UCITS ETF 23.10.2026 FTAI IE000YIQZ0H6 225,002.00 USD 6,931,537.52 30.807 View source version o
  2. EnergyJoe Amara Executive Search Tapped to Lead Head of Power Origination SearchConfidential mandate for a large independent power producer centers on large-load customers, data centers, and complex power agreements CHICAGO, October 26, 2026--Joe Amara Executive Search has been selected by a large independent power producer to lead a confidential search for a Head of Power Origination. The executive will lead commercial strategy across a national wind, solar, and battery stor
  3. EducationRegional Centres for Education cutting supports to students with exceptionalities to save money: parents, unionHALIFAX, NS, October 26, 2026--CUPE School Support workers have learned that recent layoffs of Educational Program Assistants may be tied to a directive from the province to reassess the support needs of students already receiving assistance. Shelley McNeil, president of CUPE Local 5047, Halifax Region
  4. Internet & appsGeogentiaGeogentia Launches Perimeter, Alerts-Only Threat Monitoring for Schools, Organizations, Family Offices and Places of WorshipPerimeter watches social media, the open web and the dark web for threats against the people and places a client protects, then tells their team exactly what to do next HOLLAND, Mich., October 26, 2026--Geogentia today launched Perimeter, threat monitoring for schools, organizations, family offices, pu
  5. InsuranceBerkshire Hathaway Specialty InsuranceBerkshire Hathaway Specialty Insurance Promotes Virginie Pelletier to Head of Executive & Professional Liability in FranceCompanies: Berkshire HathawayBOSTON & PARIS, October 26, 2026--Berkshire Hathaway Specialty Insurance (BHSI) today announced that it has promoted Virginie Pelletier to Head of Executive & Professional Liability (E&P) in France. "Virginie brings deep expertise, strong relationships with customers and brokers, and a highly collabora
  6. FinanceNorthern TrustNorthern Trust Reappointed by People's PensionCompanies: Northern TrustLong-standing Relationship Continues as Northern Trust Supports the Scheme's Strategic Objectives LONDON, October 26, 2026--Northern Trust (Nasdaq: NTRS) today announced it has been reappointed by People's Pension to provide fund administration, global custody, securities lending and performance measur